1525 Superior Avenue, Suite 200
Newport Beach, CA 92663
Phone (949) 650-0506
Fax (949) 999-8126

Receive our newsletter
  Home  
  Our Team  
  Patient Info  
  Contact Us  

News for Healthier Living

FDA Approves Immune Checkpoint Inhibitor Drug for Patients with Resectable Locally Advanced Head and Neck Cancer, Backed by Dana-Farber Research

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) greater than or equal to 1] as determined by an FDA-approved test.

June 13, 2025


June 14 2025

June 13 2025

June 12 2025

June 11 2025

June 10 2025

June 9 2025

June 8 2025

June 7 2025

June 6 2025

June 5 2025

June 4 2025

June 3 2025

June 2 2025

June 1 2025

May 31 2025